Kash John C, Walters Kathie-Anne, Kindrachuk Jason, Baxter David, Scherler Kelsey, Janosko Krisztina B, Adams Rick D, Herbert Andrew S, James Rebekah M, Stonier Spencer W, Memoli Matthew J, Dye John M, Davey Richard T, Chertow Daniel S, Taubenberger Jeffery K
Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Institute for Systems Biology, Seattle, WA 98109, USA.
Sci Transl Med. 2017 Apr 12;9(385). doi: 10.1126/scitranslmed.aai9321.
The 2013-2015 outbreak of Ebola virus disease in Guinea, Liberia, and Sierra Leone was unprecedented in the number of documented cases, but there have been few published reports on immune responses in clinical cases and their relationships with the course of illness and severity of Ebola virus disease. Symptoms of Ebola virus disease can include severe headache, myalgia, asthenia, fever, fatigue, diarrhea, vomiting, abdominal pain, and hemorrhage. Although experimental treatments are in development, there are no current U.S. Food and Drug Administration-approved vaccines or therapies. We report a detailed study of host gene expression as measured by microarray in daily peripheral blood samples collected from a patient with severe Ebola virus disease. This individual was provided with supportive care without experimental therapies at the National Institutes of Health Clinical Center from before onset of critical illness to recovery. Pearson analysis of daily gene expression signatures revealed marked gene expression changes in peripheral blood leukocytes that correlated with changes in serum and peripheral blood leukocytes, viral load, antibody responses, coagulopathy, multiple organ dysfunction, and then recovery. This study revealed marked shifts in immune and antiviral responses that preceded changes in medical condition, indicating that clearance of replicating Ebola virus from peripheral blood leukocytes is likely important for systemic viral clearance.
2013 - 2015年在几内亚、利比里亚和塞拉利昂爆发的埃博拉病毒病,其确诊病例数量空前,但关于临床病例免疫反应及其与埃博拉病毒病病程和严重程度关系的已发表报告却很少。埃博拉病毒病的症状可能包括严重头痛、肌痛、乏力、发热、疲劳、腹泻、呕吐、腹痛和出血。尽管实验性治疗正在研发中,但目前美国食品药品监督管理局尚未批准任何疫苗或疗法。我们报告了一项详细研究,该研究通过微阵列检测了一名重症埃博拉病毒病患者每日外周血样本中的宿主基因表达。此人在国立卫生研究院临床中心从危重症发病前到康复期间,接受了无实验性疗法的支持性治疗。对每日基因表达特征的皮尔逊分析显示,外周血白细胞中存在明显的基因表达变化,这些变化与血清和外周血白细胞变化、病毒载量、抗体反应、凝血病、多器官功能障碍以及随后的康复相关。这项研究揭示了免疫和抗病毒反应在病情变化之前的显著转变,表明从外周血白细胞中清除正在复制的埃博拉病毒可能对全身病毒清除至关重要。